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With many candidate drugs failing in the late clinical stages, drug development is a high-risk business. In 
order to reduce the high rates of attrition, a better knowledge of a drug’s mechanism of action is 
required. Hence we have developed Galahad, a web server for the analysis of gene expression data 
following drug treatment, aimed at predicting a drug’s molecular targets and physiological effects. 
INTRODUCTION 
The pharmaceutical industry is facing unprecedented 
productivity challenges. Attrition rates have risen sharply, 
especially in late-phase clinical trials. With safety and 
efficacy being the main bottlenecks, a better knowledge of 
a candidate drug’s mode of action and its off-target effects 
could be of substantial value to drug development. DNA 
microarray technology enables a genome-wide analysis on 
the transcriptional response to a compound treatment, and 
thus can provide valuable information for identifying the 
compound-protein interactions and resulting effects prior to 
clinical trials. In addition, this information may also be 
useful for already marketed drugs, in the light of drug 
repositioning. 
METHODS 
We have developed a new, easy-to-use web server called 
Galahad, for the in-depth exploration of a drug’s mode of 
effect based on gene expression changes following 
treatment. Our software provides the main tools needed for 
gaining new insights into the biological effects of a drug by 
combining  
• preprocessing of gene expression data obtained 
from different Affymetrix array types;  
• quality assessment and exploratory analysis of 
these data to ascertain data quality, uncover 
experimental issues or sample mix-us, and help in 
deciding whether certain arrays need to be 
considered as outlying; 
• differential expression analysis to determine the 
significance of gene up- or down-regulation 
following drug treatment by fitting a linear model 
to the expression data for each gene; 
• genome-wide drug target prioritization by 
means of an in-house developed algorithm for 
network neighborhood analysis integrating the 
expression data with functional protein association 
information1;  
• prediction of Reactome pathways involved in the 
drug’s mode of effect;  
• identification of associated disease phenotypes 
from the Human Phenotype Ontology enabling 
side effect prediction and drug repositioning. 
RESULTS & DISCUSSION 
All of the above functionalities can be demonstrated on 
gene expression data for treatment with drugs exhibiting a 
well-defined mechanism of action. One such drug is 
infliximab, a tumor necrosis factor (TNF)-binding 
monoclonal antibody marketed under the brand name 
Remicade and used in the treatment of several autoimmune 
diseases. Infliximab target prioritization based on the gene 
expression profiles from eleven Crohn’s colitis patients 
treated with this drug2 ranks the target TNF in the top 1%, 
although not differentially expressed following treatment. 
Enrichment analysis on the significantly up- and down-
regulated genes returned several immune pathways, as well 
as links to disease phenotypes reported in literature either 
as a known indication, a side effect, or a possibility for 
repositioning. By application to a larger set of well-
characterized chemical drugs, Galahad will now be further 
optimized. 
 
 
FIGURE 1. Overview of analyses provided by Galahad. 
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